Publicaciones en las que colabora con Eva Ciruelos (13)

2020

  1. Phase III study to evaluate patient’s preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07)

    European Journal of Cancer Care, Vol. 29, Núm. 4

2019

  1. Contribution of trastuzumab to the prognostic improvement of HER2-positive early breast cancer in Spain: An estimation of life years and disease-free life years gained since its approval

    Oncotarget, Vol. 10, Núm. 42, pp. 4321-4332

2018

  1. Primary results of the first nationwide molecular screening program in Spain for patients with advanced breast cancer (AGATA SOLTI-1301 study)

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii90

2017

  1. A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)

    Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 616-624

2016

  1. Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: Patient-reported outcomes in the suppression of ovarian function trial

    Journal of Clinical Oncology, Vol. 34, Núm. 14, pp. 1601-1610

  2. Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile

    Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428

  3. Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): The SOFT-EST substudy

    Journal of Clinical Oncology, Vol. 34, Núm. 14, pp. 1584-1593

2014

  1. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): Follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort

    The Lancet Oncology, Vol. 15, Núm. 6, pp. 640-647

  2. Trastuzumab in small tumours and in elderly women

    Cancer Treatment Reviews, Vol. 40, Núm. 1, pp. 41-47

2013

  1. Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain

    Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 13, Núm. 3, pp. 381-391

2012

  1. Pathological complete response rates following different neoadjuvant chemotherapy regimens for Operable Breast Cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II)

    Breast Cancer Research and Treatment, Vol. 132, Núm. 3, pp. 843-851

2010

  1. Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: A multicenter phase II study (SOLTI 0301 trial)

    Annals of Oncology, Vol. 21, Núm. 7, pp. 1442-1447

  2. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

    The Lancet, Vol. 375, Núm. 9712, pp. 377-384